Results 11 to 20 of about 4,101 (234)

Clinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center [PDF]

Advances in Hematology
Patients with chronic lymphocytic leukemia (CLL) treated with covalent Bruton’s tyrosine kinase inhibitors (BTKi) eventually discontinue treatment, but data on outcomes post-BTKi treatment discontinuation are limited.
Mohammed Farooqui, Jennifer R Brown, Matthew S Davids   +2 more
exaly   +6 more sources

Immune response to COVID‐19 vaccination in patients with Waldenström macroglobulinaemia who pause their BTKi therapy [PDF]

eJHaem, 2023
Patients with Waldenström macroglobulinaemia (WM) are at increased risk of severe COVID‐19 infection and have poor immune responses to COVID‐19 vaccination. This study assessed whether a closely monitored pause in Bruton's Tyrosine Kinase inhibitor (BTKi)
Katherine Rankin, Priyanka Hastak, Alexander Wong, Sarah C. Sasson, Brendan Beaton, Avani Yeola, Andrew Warden, Stuart Turville, Anthony D. Kelleher, Fabienne Brilot, Judith Trotman   +10 more
doaj   +6 more sources

Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation [PDF]

Journal of Hematology and Oncology, 2022
Abstract Background Post-market analyses revealed unanticipated links between first-generation Bruton’s tyrosine kinase inhibitor (BTKi) therapy, ibrutinib, and profound early hypertension. Yet, whether this is seen with novel selective second (next)-generation BTKi therapy, acalabrutinib, is unknown.
John Alan Gambril, Sujay Kalathoor, Kerry A Rogers   +2 more
exaly   +5 more sources

Cardiotoxicity from bruton tyrosine kinase inhibitors (BTKi)—an analysis of an administrative health claims database

Cardio-Oncology
Background First generation Bruton tyrosine kinase inhibitors (BTKi) such as ibrutinib have been associated with cardiovascular toxicities. Newer generation BTKi (e.g.,acalabrutinib and zanabrutinib) have been associated with lower incidence of ...
Srilakshmi Vallabhaneni, Srinath Adusumalli, Jingyi Wu, Peter W. Groeneveld, James Gerson, Rupal P. O’Quinn   +5 more
exaly   +4 more sources

Predictors and responses to varying durations of BTK inhibitor bridging therapy before anti-CD19 CAR-T cell therapy in patients with relapsed/refractory DLBCL [PDF]

Frontiers in Immunology
BackgroundAnti-CD19 chimeric antigen receptor (CAR)-T cell therapy has demonstrated clinical potential in treating relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL); however, enhancing its therapeutic efficacy remains a significant ...
Jia Wang, Rui Cui, Yao Qi, Juan Mu, Xin Li, Qing Li, Qi Deng   +6 more
doaj   +2 more sources

Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents

Journal of Hematology and Oncology, 2023
Mantle cell lymphoma is a B cell non-Hodgkin lymphoma (NHL), representing 2–6% of all NHLs and characterized by overexpression of cyclin D1. The last decade has seen the development of many novel treatment approaches in MCL, most notably the class of ...
Lalit Sehgal, Narendranath Epperla, Neeraj Jain   +2 more
exaly   +2 more sources

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 studyResearch in context [PDF]

EClinicalMedicine, 2023
Summary: Background: Parsaclisib is a potent and highly selective PI3Kδ inhibitor that has shown clinical benefit in patients with relapsed/refractory (R/R) B-cell malignancies.
Pier Luigi Zinzani, Marek Trněný, Vincent Ribrag, Vittorio Ruggero Zilioli, Jan Walewski, Jacob Haaber Christensen, Vincent Delwail, Guillermo Rodriguez, Parameswaran Venugopal, Morton Coleman, Caroline Dartigeas, Caterina Patti, Fabrizio Pane, Wojciech Jurczak, Michal Taszner, Shankara Paneesha, Fred Zheng, Douglas J. DeMarini, Wei Jiang, Aidan Gilmartin, Amitkumar Mehta   +20 more
doaj   +3 more sources

Severe atypical skin disease in two patients with CLL/SLL after BTKi treatment - a case report and literature review

Frontiers in Oncology
Dermatological adverse events (AEs) are generally mild during therapy with Bruton’s tyrosine kinase inhibitor (BTKi), and it is often unnecessary to adjust the BTKi dosage or discontinue treatment.
Jingxin Zhou, Wentong Ma, Na Hu, Yuhan Ma, Huayuan Zhu, Ling Gao   +5 more
doaj   +2 more sources

Expanded CD16+CD56+Granzyme B+ NK like CD8+ T cells an off target effect of bruton’s tyrosine kinase inhibitors in Waldenström macroglobulinemia [PDF]

Scientific Reports
Bruton’s tyrosine kinase inhibitors (BTKi), widely used in Waldenström macroglobulinemia (WM), are known to impair B cell function, but their broader immunological effects remain unclear.
Priyanka Hastak, Chansavath Phetsouphanh, Zong-Hong Zhang, Rowena A. Bull, Lok Bahadur Shrestha, Vera Klemm, Raymond Louie, Fabio Luciani, C. Mee Ling Munier, Alexandra Carey Hoppé, Elizabeth Keoshkerian, Brendan Beaton, Katherine Rankin, Alexander Wong, Judith Trotman, Anthony D. Kelleher, Sarah C. Sasson   +16 more
doaj   +2 more sources

Bortezomib‐based therapy is effective and well tolerated in frontline and multiply pre‐treated Waldenström macroglobulinaemia including BTKi failures: A real‐world analysis

EJHaem, 2022
Waldenström macroglobulinemia (WM) is a rare, incurable low grade lymphoma following a relapsing trajectory. Management strategies have evolved with the introduction of targeted therapy including new classes of Bruton tyrosine kinase inhibitor (BTKi ...
Jahanzaib Khwaja
exaly   +2 more sources